Novel Buprenorphine Induction Strategies | July 6, 2021
Date of Presentation: July 6, 2021
Type: Past Presentation
Audience: Clinical
Program: Advancing Pharmacist Roles in Substance Use Disorder Treatment and Recovery Teams
Keywords: #buprenorphine #novel buprenorphine induction
In this presentation, Dr. Gasper discusses novel buprenorphine induction strategies.
Recording:
Presented by:
Dr. James J. Gasper, PharmD, BCPP
Dr. James J. Gasper received his Doctorate of Pharmacy from the University of Colorado. He completed his pharmacy practice residency at the Denver Veterans Affairs Medical Center and psychiatric pharmacy residency at the University of California San Francisco. Dr. Gasper has spent the last 18 years developing, implementing, and working in substance use disorder treatment and specialty mental health with an emphasis on opioid use disorder, methamphetamine addiction, and co-occurring disorders. He is currently a substance use specialist for the UCSF National Clinician Consultation Center Substance Abuse Warmline.
Resources Provided:
- Novel Buprenorphine Induction Strategies (Presentation Slides)
- Treatment Improvement Protocol (TIP) Series 40 (SAMHSA)
- Treatment Improvement Protocol (TIP) Series 63 (SAMHSA)
- Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients (Biol Psych)
- Sublingual Buprenorphine/Naloxone Precipitated Withdrawal in Subjects Maintained on 100 mg of Daily Methadone (Drug Alcohol Depend)
- Effects of Buprenorphine Maintenance Dose on Mu-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers (Neuropsychopharmacology)
- Use of Microdoses for Induction of Buprenorphine Treatment with Overlapping Full Opioid Agonist Use: The Bernese Method (Substance Abuse and Rehab)
- Short Communication: Systematic Review on Effectiveness of Micro-induction Approaches to Buprenorphine Initiation (Addictive Behaviors)
- Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market (CMAJ)
Date added: July 6, 2021